Literature DB >> 28133918

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.

M Alcasid1, L Ma1, J R Gotlib1, D A Arber1, R S Ohgami1.   

Abstract

INTRODUCTION: While the role of the immune system in altering and modulating the progression of solid tumors is well studied, the impact of the immune system on the outcome and progression of hematolymphoid neoplasms is still poorly understood.
METHODS: Here, we report a retrospective study detailing our analysis of 130 patients with acute myeloid leukemia (AML), with flow cytometry immunophenotypic evaluation of major lymphocyte subsets including B cells, T cells, and NK cells.
RESULTS: Our study identifies differential signatures of lymphocyte subsets pertaining to distinct subcategories of AML, and prognostic correlations in patients. In multivariate analysis, NK cells (specifically CD56+/CD16+ NK cells at a cutoff of ≥5%) were found to be an independent indicator of improved overall and disease-free survival; cytogenetic risk was also shown to be critical in stratifying patients with AML.
CONCLUSIONS: In total, we demonstrate that in AML, the subset distribution of immune system lymphocytes is nonrandom, and suggest an important role for distinct lymphocyte subsets, particularly NK cells, in this disease.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Immune system; acute myeloid leukemia; immunosurveillance

Mesh:

Year:  2017        PMID: 28133918     DOI: 10.1111/ijlh.12594

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  6 in total

1.  Clinical Impact of Percentage of Natural Killer Cells and Natural Killer-Like T Cell Population in Acute Myeloid Leukemia.

Authors:  Esraa Jamal; Emad Azmy; Mohamed Ayed; Salah Aref; Noha Eisa
Journal:  J Hematol       Date:  2020-08-14

2.  The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia.

Authors:  Yumi Park; Jinsook Lim; Seonyoung Kim; Ikchan Song; Kyechul Kwon; Sunhoe Koo; Jimyung Kim
Journal:  Blood Res       Date:  2018-09-28

Review 3.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Authors:  Mattias Carlsten; Marcus Järås
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

4.  Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.

Authors:  Guoqiang Lin; Yanming Zhang; Lei Yu; Depei Wu
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

5.  Study of Bone Marrow Lymphocyte Subset in Acute Myeloid Leukemia.

Authors:  Prasad Dange; Seema Tyagi; Richa Juneja; Tulika Seth; Renu Saxena
Journal:  J Lab Physicians       Date:  2021-07-29

Review 6.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.